CompoAtlas

Ambrosial Milk Thistle Liver Detox 60 Capsules

Complemento alimenticio declarado en Francia, decisión del 10 de julio de 2026

Ambrosial Milk Thistle Liver Detox 60 Capsules, de la empresa Ambrosial Nutrifood Ltd, es un complemento alimenticio declarado en Francia. Estado: declarado en Francia, comercialización posible. Ingredientes principales: Silybum marianum 200 mg al día, Taraxacum campylodes 50 mg al día, Cichorium intybus 50 mg al día, Curcuma longa 25 mg al día, Glycyrrhiza glabra 25 mg al día. 1 norma de uso se aplica a sus ingredientes (límites y advertencias).

Marca
no indicada
Responsable de la comercialización
Ambrosial Nutrifood Ltd
Estado
Declarado en Francia, comercialización posible: la administración no se opuso a la declaración (no es una autorización ni una evaluación de seguridad)
Forma
Cápsula
Dosis diaria

Texto original en francés.

1 capsule per day

Compl’Alim, declaraciones de complementos alimenticios ·

Notificación 366879, procedimiento Article 15. Compl’Alim, declaraciones de complementos alimenticios, consultado el 15 de noviembre de 2026.

Composición declarada

Plantas

PlantaPartePreparaciónAl día
Silybum marianum (L.) Gaertn.GraineAutre extrait sec200 mg
Taraxacum campylodes G.E.HaglundRacineAutre extrait sec50 mg
Cichorium intybus L.RacineAutre extrait sec50 mg
Curcuma longa L.RhizomeAutre extrait sec25 mg
Glycyrrhiza glabra L.RacineAutre extrait sec25 mg
Phyllanthus emblica L.FruitAutre extrait sec25 mg
Phyllanthus niruri L.Plante entièreAutre extrait sec25 mg
Picrorhiza kurroa RoyleRacineAutre extrait sec25 mg
Zingiber officinale RoscoeRhizomeAutre extrait sec20 mg
Piper nigrum L.FruitAutre extrait sec5 mg

Lista de la declaración, decisión de la administración del (Compl’Alim, declaraciones de complementos alimenticios).

¿Ha cambiado el producto? Fotografíe el envase.

Aspectos reglamentarios

Esta información recoge la declaración del fabricante ante la Administración (DGAL). No indica si el producto es eficaz ni sustituye el consejo de un médico o farmacéutico, especialmente durante el embarazo o un tratamiento.

Advertencias oficiales (Health Canada)

Health Canada publica advertencias sobre estos ingredientes:

  • Silybum marianum (L.) Gaertn.
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    MILK THISTLE - SILYBUM MARIANUM

    Vía de administración: Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills et al. 2006).

    Fuentes citadas por Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills E, Dugoua J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (UK): Taylor and Francis Medical; 2006.

    Reacciones adversas conocidas

    Stop use if hypersensitivity/allergy occurs (Geier et al. 1990; Mironets et al. 1990).

    Fuentes citadas por Health Canada (2)
    • Geier J, Fuchs Th, Wahl R. [Anaphylactic shock due to an extract of Silybum marianum in a patient with immediate-type allergy to Kiwi fruit]. Anaphylaktischer Schock durch einen Mariendistel-Extrakt bei Soforttyp-Allergie auf Kiwi. Allergologie 1990;13(10):387-388 (in German).
    • Mironets VI, Krasovskaia EA, Polischuk II. [A case of urticaria during carsil treatment]. Vrachebnoe Delo 1990;(7):86-87 (in Russian).

    Monografía de Health Canada del 26 de junio de 2026

  • Taraxacum campylodes G.E.Haglund
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    DANDELION - TARAXACUM OFFICINALE

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder or an intestinal obstruction (Brinker 2010; Godfrey et al. 2010; ESCOP 2003; Bradley 1992).

    Fuentes citadas por Health Canada (5)
    • Bradley PR, editor. 1992. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products. 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Godfrey A, Saunders P, Barlow K, Gowan M. Principles and Practices of Naturopathic Botanical Medicine: Volume 1: Botanical Medicine Monographs, 1st edition. Toronto (ON): CCNM Press Inc.; 2010.
    • EMA 2009: European Medicines Agency, Science Medicines Health. 12 November 2009. EMA/HMPC/212895/2008. Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Taraxacum officinale Weber ex Wigg., radix cum herba. Final. [Consulté le 14 mars 2024]. Disponible à : https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf

    Condición de aplicación: Constipation, Flushing of the urinary tract, Indigestion, and Loss of appetite.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindicaciones

    Se aplica a los productos: providing 10 g or more of dried leaf or dried root or dried whole plant, per day or 10 mL or more of juice, per day.

    Do not use if you have diabetes or a blood pressure, kidney or cardiovascular disorder (Goksu et al. 2010; EMA 2009; Hunt et al. 2005; Green et al. 2002; Mujais and Katz 2000; Carlsen et al. 1990; Kuller et al. 1986; Artz et al. 1966).

    Fuentes citadas por Health Canada (8)
    • Artz SA, Paes IC, Faloon WW. Hypokalemia-induced hepatic coma in cirrhosis. Occurrence despite neomycin therapy. Gastroenterology 1966;51(6):1046-1053. PubMed
    • Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. British Medical Journal 1990;300(6730):975-978. PubMed Ensayo aleatorizado
    • EMA 2009: European Medicines Agency, Science Medicines Health. 12 November 2009. EMA/HMPC/212895/2008. Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Taraxacum officinale Weber ex Wigg., radix cum herba. Final. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf
    • Goksu E, Eken C, Karadeniz O, Kucukyilmaz O, Firt report of hypoglycemia secondary to dandelion (Taraxacum officinale) ingestion. The American Journal of Emergency Medicine 2010;28:111.e1-111.e2
    • Green DM, Ropper AH, Kronmal RA, Psaty BM, Burke GL. Serum potassium level and dietary potassium intake as risk factors for stroke. Neurology 2002;59(3):314-320. PubMed
    • Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith Jr. SC, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154-235.
    • Kuller LH, Hulley SB, Cohen JD, Neaton J. Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis. Circulation 1986;73(1):114-123. PubMed
    • Mujais SK, Katz AL. Potassium deficiency. In: Seldin & Giebisch's The Kidney: Physiology and Pathophysiology. Lippincott Williams and Wilkins; 2000. p1615.

    Do not use if you are taking heart medications or other products containing diuretics (Goksu et al. 2010; EMA 2009; Hunt et al. 2005; Green et al. 2002; Mujais and Katz 2000; Carlsen et al. 1990; Kuller et al. 1986; Artz et al. 1966).

    Fuentes citadas por Health Canada (8)
    • Artz SA, Paes IC, Faloon WW. Hypokalemia-induced hepatic coma in cirrhosis. Occurrence despite neomycin therapy. Gastroenterology 1966;51(6):1046-1053. PubMed
    • Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. British Medical Journal 1990;300(6730):975-978. PubMed Ensayo aleatorizado
    • EMA 2009: European Medicines Agency, Science Medicines Health. 12 November 2009. EMA/HMPC/212895/2008. Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Taraxacum officinale Weber ex Wigg., radix cum herba. Final. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf
    • Goksu E, Eken C, Karadeniz O, Kucukyilmaz O, Firt report of hypoglycemia secondary to dandelion (Taraxacum officinale) ingestion. The American Journal of Emergency Medicine 2010;28:111.e1-111.e2
    • Green DM, Ropper AH, Kronmal RA, Psaty BM, Burke GL. Serum potassium level and dietary potassium intake as risk factors for stroke. Neurology 2002;59(3):314-320. PubMed
    • Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith Jr. SC, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154-235.
    • Kuller LH, Hulley SB, Cohen JD, Neaton J. Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis. Circulation 1986;73(1):114-123. PubMed
    • Mujais SK, Katz AL. Potassium deficiency. In: Seldin & Giebisch's The Kidney: Physiology and Pathophysiology. Lippincott Williams and Wilkins; 2000. p1615.

    Monografía de Health Canada del 25 de julio de 2025

  • Curcuma longa L.
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    TURMERIC - CURCUMA LONGA - Oral

    Vía de administración: Oral (ESCOP 2003; Blumenthal et al. 2000)

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).

    Fuentes citadas por Health Canada (2)
    • ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.

    1 estudio citado en el texto no tiene referencia correspondiente en la monografía (véanse las anomalías en la página de fuentes).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).

    Fuentes citadas por Health Canada (6)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2018. European Medicines Agency. European Union herbal monograph on Curcuma longa L., rhizome. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 25 September 2018. [Accessed 2023 October 14] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf
    • ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).

    Fuentes citadas por Health Canada (2)
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).

    Fuentes citadas por Health Canada (2)
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Condición de aplicación: All uses except for Source of antioxidants and Hepatoprotectant.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 26 de septiembre de 2025

    Turmeric -CURCUMA LONGA - Topical

    Precauciones y advertencias

    For external use only.

    When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Contraindicaciones

    Do not use on deep or puncture wounds, animal bites or serious burns.

    Monografía de Health Canada del 28 de febrero de 2025

  • Glycyrrhiza glabra L.
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    DEGLYCYRRHIZINATED LICORICE Buccal

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 31 de octubre de 2025

    Deglycyrrhizinated Licorice Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 31 de enero de 2025

    LICORICE

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Gardner and McGuffin 2013).

    Fuentes citadas por Health Canada (1)
    • Gardner Z, McGuffin M. editors. 2013. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press.

    Condición de aplicación: Cough relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if cough worsens or persists (for) more than 1 week (EMA 2012).

    Fuentes citadas por Health Canada (1)
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf

    Condición de aplicación: Gastritis relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindicaciones

    Condición de aplicación: All products.

    Do not use if you are pregnant (EMA 2012).

    Fuentes citadas por Health Canada (2)
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
    • Gardner Z, McGuffin M. éditeurs. 2013. American Herbal Products Association's Botanical Safety Handbook, 2e édition. Boca Raton (FL): CRC Press.

    Do not use if you have hypokalemia, high blood pressure, or a kidney, liver or cardiovascular disorder (EMA 2012; Brinker 2010; ESCOP 2003; Bradley 1992).

    Fuentes citadas por Health Canada (4)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (UK): British Herbal Medicine Association; 1992.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Do not use if you are taking heart medications, corticosteroids, stimulant laxatives, or other health products that may contribute electrolyte imbalance (Brinker 2010; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000).

    Fuentes citadas por Health Canada (4)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.

    Monografía de Health Canada del 29 de noviembre de 2024

  • Phyllanthus emblica L.
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    Amla - Phyllanthus Emblica

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (HC 2009).

    Fuentes citadas por Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Se aplica a los productos: providing more than 3 grams of amla, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (HC 2009).

    Fuentes citadas por Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Condición de aplicación: Amlapitta, Digestive tonic.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condición de aplicación: Laxative.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (HC 2009; Pray 2006; CPhA 2002).

    Fuentes citadas por Health Canada (3)
    • CPhA 2002: Repchinsky C, editor-in-chief. Patient Self-Care: Helping Patients Make Therapeutic Choices. 1st edition. Ottawa (ON): Canadian Pharmacists Association; 2002.
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
    • Pray WS. Non-Prescription Product Therapeutics. 2nd edition. New York (NY): Lippincott Williams & Wilkins; 2006.

    Contraindicaciones

    Condición de aplicación: Laxative.

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).

    Fuentes citadas por Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Reacciones adversas conocidas

    Condición de aplicación: Amlapitta, Antioxidant, Digestive tonic, Rasayana or Eye tonic.

    When using this product you may experience a laxative effect.

    Monografía de Health Canada del 28 de marzo de 2025

  • Picrorhiza kurroa Royle
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    KUTKI - PICRORHIZA KURROOA

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: Bitter tonic; Laxative.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindicaciones

    Condición de aplicación: All products.

    Do not use if you are pregnant or breastfeeding (Brinker 2010).

    Fuentes citadas por Health Canada (1)
    • Brinker F. Herbal Contraindications and Drug Interactions: Plus Herbal Adjuncts with Medicines, expanded 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).

    Fuentes citadas por Health Canada (2)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard. Ottawa (ON): Drugs and Health Products; Health Canada. [Accessed 2024 January 6]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
    • SC 2009: Santé Canada. Laxatifs : Général. Norme d'Étiquetage des Laxatifs. Ottawa (ON): Médicaments et produits de santé, 2009. [Consulté le 6 janvier 2024]. Disponible à: https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/medicaments-vente-libre-normes-etiquetages-produits-pharmaceutiques/laxatifs-normes-etiquetages-medicaments-vente-libre.html

    Reacciones adversas conocidas

    Condición de aplicación: Bitter tonic; Liver protectant.

    When using this product you may experience a laxative effect (Sudarshan 2005; API 2001; Kapoor 2001).

    Fuentes citadas por Health Canada (3)
    • API 2001: The Ayurvedic Pharmacopoeia of India. Part I, Volume II, 1st edition. Delhi (IN): The Controller of Publications; 1991. [Accessed 2018 August 14]. Available from: http://www.ayurveda.hu/api/API-Vol-2.pdf
    • Kapoor LD. Handbook of Ayurvedic Medicinal Plants. Baton Roca (FL): CRC Press LLC; 2001.
    • Sudarshan SR. Encyclopaedia of Indian Medicine, Materia Medica-Herbal Drugs.Volume 4.Banglore (IN): Popular Prakashan; 2005.

    Monografía de Health Canada del 26 de julio de 2024

  • Zingiber officinale Roscoe
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    GINGER - ZINGIBER OFFICINALE

    Vía de administración: Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 19 de diciembre de 2025

Se refieren al ingrediente, no a este producto ni a su dosis. No sustituyen el consejo médico.

¿Alguna información inexacta o más reciente sobre este producto, sea usted lector o marca? Escriba a contact@compoatlas.com: cada corrección se publica en el registro de correcciones.

Intro para analizar, Mayús+Intro para una nueva línea